DOI: 10.36347/sjams.2017.v05i03.022

Pages: 800-804

Internationally it is estimated that around 273,000 new cases of multidrug-resistant tuberculosis (MDR-TB, resistant to isoniazid and rifampicin) occurs every year. To improvise and efiiciently manage MDR-TB in the context of the DOTS strategy, WHO and partners have been piloting an expanded treatment strategy called DOTS-Plus. However, standard definitions for MDR-TB registration or Statndard Operating Procedures (SOP’s) treatment outcomes do not exist. We document a set of definitions and standards to assess treatment outcomes of MDR-TB patients under the DOTS strategy.